The American College of Obstetricians and Gynecologists (ACOG) has issued updated guidelines endorsing hormone therapy as a preferred treatment for common menopausal symptoms such as hot flashes, night sweats, and related sleep disturbances. The recommendations, released last week, emphasize individualized care and flexibility in treatment duration and dosage.
Hormone therapy is strongly recommended for patients without contraindications, including those with a history of blood clots, stroke, or certain cancers. For patients at elevated risk or those unwilling to use hormones, the guidelines suggest alternative options. These include newer medications that target brain receptors involved in temperature regulation, certain antidepressants that have shown efficacy in reducing hot flashes, and, to a lesser extent, cognitive behavioral therapy, although evidence supporting the latter remains limited.
The updated guidance aligns closely with recent recommendations from the American College of Physicians and marks a shift toward personalized decision-making rather than rigid limitations on treatment length or dosage. While previous ACOG guidelines from 2014 favored hormone therapy at the lowest effective dose and shortest duration, the new recommendations recognize that some individuals may need to continue therapy beyond age 60 or more than 10 years past menopause to manage persistent symptoms effectively.
Dr. Catherine Cansino, chair of the ACOG committee behind the guidance, emphasized the importance of tailoring treatment to individual patient needs instead of adhering to prescriptive rules. The designation of a “strong” recommendation reflects ACOG’s assessment that the benefits of hormone therapy for treating vasomotor symptoms outweigh associated risks in most patients.
However, the guidelines caution that uncertainties remain regarding hormone therapy’s potential risks, including breast cancer and cardiovascular events. To guide clinical decision-making, physicians are advised to utilize tools such as the American College of Cardiology’s cardiovascular risk calculator and the National Cancer Institute’s breast cancer risk assessment, though the guidelines do not specify thresholds for contraindications or treatment cessation.
Experts highlight the complexity of risk assessment in this context. Dr. Stephanie Faubion of the Mayo Clinic noted that while some patients may have clear contraindications, others might safely opt for hormone therapy after careful evaluation and discussion of risks and benefits. She also pointed out that different hormone therapy formulations, such as transdermal patches, may carry varying risk profiles, potentially offering safer alternatives for some women.
The new guidance focuses primarily on managing hot flashes, night sweats, sleep disturbances, and mood changes, postponing recommendations on other menopausal issues such as genitourinary syndrome of menopause, which includes symptoms like vaginal dryness and urinary tract infections. ACOG plans to release separate advice on these conditions in the coming year.
Endocrinologist Dr. JoAnn Manson, who was not involved in developing the guidelines, welcomed the new recommendations, noting a growing consensus among medical societies that menopausal symptoms warrant treatment and that hormone therapy remains the most effective option. She clarified that the guidance does not support hormone therapy for the prevention of diseases such as heart disease or cognitive decline in asymptomatic women, a practice that was more common before findings from the Women’s Health Initiative study in the early 2000s.
Overall, the updated guidelines aim to promote more personalized and proactive management of menopausal symptoms, encouraging clinicians and patients to weigh benefits and risks carefully and consider a broader range of treatment options.